Jefferies Reiterates Buy on Integra LifeSciences, Slashes PT to $55

Jefferies reiterated its Buy rating on Integra LifeSciences IART. At the same time, the rating agency reduced its price target on the company's stock from $58 to $55. On Thursday, IART added 0.28% to its value to end the day at $45.85.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Price TargetReiterationAnalyst RatingsHealth CareHealth Care EquipmentJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!